Arcus downgraded at Morgan Stanley on balanced risk-reward setup
Source: SeekingAlpha
2026-01-08 12:42:09 ET
More on Arcus Biosciences
- Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221
- Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets
- Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
Read the full article on Seeking Alpha
For further details see:
Arcus downgraded at Morgan Stanley on balanced risk-reward setup
ProShares Ultra Nasdaq Biotechnology
NASDAQ: BIB
BIB Trading
3.63% G/L:
$82.01 Last:
8,399 Volume:
$81.81 Open:
